Clinical Trials
2 trialsNCT03112603 2025-08-12
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Phase 3 Completed
NCT02957266 2016-11-15
CERVIPIB
The National Center of Oncology, Azerbaijan
Phase 3 Unknown